AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7957520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Number of subjects: 9
Study 3122595 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl/nitrous oxide anaesthesia
Number of subjects: 100
Study 3122595 — intervention group
Group type: COMPARATOR
Intervention: Antagonised midazolam anaesthesia (midazolam/fentanyl/isoflurane/nitrous oxide with flumazenil 1 mg)
Number of subjects: 100
Study 31230088 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐DCFPyL PET/CT
Number of subjects: 248
Study 28554939 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified clinical algorithm for ART initiation (SLATE)
Number of subjects: 960
Study 28554939 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (routine, standard of care ART initiation)
Number of subjects: 960
Study 24620734 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for exercise during pregnancy
Number of subjects: 127
Study 24620734 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for exercise during pregnancy and post-partum period until 2 months after delivery
Number of subjects: 127
Study 24620734 — intervention group
Group type: COMPARATOR
Intervention: No intervention group
Number of subjects: 127
Study 23723457 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose oseltamivir (150 mg twice a day)
Number of subjects: 326
Study 23723457 — intervention group
Group type: COMPARATOR
Intervention: Standard dose oseltamivir (75 mg twice a day)
Number of subjects: 326
Study 23723457 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose oseltamivir
Number of subjects: 326
Study 23723457 — intervention group
Group type: COMPARATOR
Intervention: Standard dose oseltamivir
Number of subjects: 326
Study 21986780 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (5 g daily) and boswellic acids (7.2 mg daily)
Number of subjects: 60
Study 21986780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19485978 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated‐interferon‐alpha2a (180 microg once weekly) plus ribavirin (1000‐1200 mg/daily) with amantadine (200 mg/daily)
Number of subjects: 630
Study 19485978 — intervention group
Group type: COMPARATOR
Intervention: pegylated‐interferon‐alpha2a (180 microg once weekly) plus ribavirin (1000‐1200 mg/daily) without amantadine
Number of subjects: 630
Study 17018656 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (300 mg elemental Mg per day in two divided doses)
Number of subjects: 120
Study 17018656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15339258 — intervention group
Group type: COMPARATOR
Intervention: Auditory (AD) stimulation alone
Number of subjects: 10
Study 15339258 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile (VT) + Auditory (AD) stimulation
Number of subjects: 10
Study 15339258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined VT + AD stimulation
Number of subjects: 10
Study 14641355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepanthol Handbalsam containing 5% dexpanthenol
Number of subjects: 25
Study 14641355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11166015 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dietary treatment (50% to 55% carbohydrate and 30% fat for 2 months)
Number of subjects: 30
Study 11166015 — intervention group
Group type: COMPARATOR
Intervention: No diet applied (control group)
Number of subjects: 30
Study 8848058 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day preparatory programme (medical information, relaxation exercises, group discussions)
Number of subjects: 223
Study 8848058 — intervention group
Group type: COMPARATOR
Intervention: 2-hour information programme
Number of subjects: 223
Study 1538094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 120
Study 1538094 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution
Number of subjects: 120
Study 6397849 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxepin for 4 weeks
Number of subjects: 51
Study 6397849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30919997 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment for up to 10 years
Number of subjects: 1343
Study 30550334 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation intervention (VPI) - role models descending the same staircase
Number of subjects: 90
Study 30550334 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation intervention (VPI) - role models descending an unfamiliar staircase
Number of subjects: 90
Study 30550334 — intervention group
Group type: COMPARATOR
Intervention: Control group - irrelevant control video
Number of subjects: 90
Study 27176871 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic follicular unit graft selection
Number of subjects: 24
Study 27176871 — intervention group
Group type: COMPARATOR
Intervention: Random follicular unit harvesting (control)
Number of subjects: 24
Study 24691680 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (n = 27)
Number of subjects: 52
Study 24691680 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n = 25)
Number of subjects: 52
Study 22980301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high dose of furosemide with hypertonic saline solution (HSS)
Number of subjects: 248
Study 22980301 — intervention group
Group type: COMPARATOR
Intervention: Intravenous high dose of furosemide without hypertonic saline solution (Control group)
Number of subjects: 248
Study 20591795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone reminder call by community peer volunteers
Number of subjects: 3880
Study 20591795 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) arm
Number of subjects: 3880
Study 18974539 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% povidone-iodine mouth rinse
Number of subjects: 45
Study 18974539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouth rinse
Number of subjects: 45
Study 18974539 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 45
Study 15802780 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D metabolite
Number of subjects: 0
Study 11845758 — intervention group
Group type: EXPERIMENTAL
Intervention: CathSim Intravenous Training System (CathSim ITS)
Number of subjects: 28
Study 11845758 — intervention group
Group type: COMPARATOR
Intervention: Plastic arm (control group)
Number of subjects: 28
Study 10502570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate solution (Fermavisc)
Number of subjects: 70
Study 10502570 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 70
Study 7570720 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional TOF MRA
Number of subjects: 176
Study 7570720 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional TOF MRA
Number of subjects: 176
Study 7570720 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex Ultrasonography (DU)
Number of subjects: 176
Study 7570720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of three-dimensional TOF MRA and DU
Number of subjects: 176
Study 7570720 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA)
Number of subjects: 176
Study 7570720 — intervention group
Group type: COMPARATOR
Intervention: Contrast Arteriography (CA)
Number of subjects: 176
Study 2407875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with reduced total and saturated fat intake, substituting low-fat meats and dairy products for high-fat options.
Number of subjects: 0
Study 2407875 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from the Cholesterol Lowering Atherosclerosis Study.
Number of subjects: 0
Study 2407875 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of lauric, oleic, and linoleic acids.
Number of subjects: 0
Study 2407875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy sources including protein, carbohydrate, alcohol, total fat, and polyunsaturated fat.
Number of subjects: 0
Study 37879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 12 weeks to reduce supine BP to 150/90 mmHg or below
Number of subjects: 24
Study 37879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 12 weeks
Number of subjects: 24
Study 37879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 24
Study 31843386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg per day from the second to the twentieth day after surgery
Number of subjects: 60
Study 31843386 — intervention group
Group type: COMPARATOR
Intervention: No diuretic (control)
Number of subjects: 60
Study 30744676 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with Yishen Granule (YSG)
Number of subjects: 240
Study 30744676 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture with placebo herbal medicine
Number of subjects: 240
Study 30744676 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with YSG
Number of subjects: 240
Study 30744676 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with placebo herbal medicine
Number of subjects: 240
Study 30744676 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with YSG
Number of subjects: 240
Study 29064991 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 76
Study 29064991 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA / AbobotulinumtoxinA
Number of subjects: 76
Study 26939322 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing technique with consciousness conduction involved (Group A)
Number of subjects: 108
Study 26939322 — intervention group
Group type: COMPARATOR
Intervention: Reducing technique with needle rotation (Group B)
Number of subjects: 108
Study 23745725 — intervention group
Group type: EXPERIMENTAL
Intervention: ZrSiO4 -ceramic crowns
Number of subjects: 223
Study 23745725 — intervention group
Group type: COMPARATOR
Intervention: Gold crowns
Number of subjects: 223
Study 21344144 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-immunoglobulins (Cytotect Biotest) for 12 months and short Ganciclovir or Valganciclovir therapy from 21th to 42th postoperative day followed by acyclovir up to 24 months
Number of subjects: 57
Study 21344144 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir for 24 months
Number of subjects: 57
Study 20329441 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturo fruit bar (50 grams carbohydrate)
Number of subjects: 11
Study 20329441 — intervention group
Group type: COMPARATOR
Intervention: Glucose standard (50 grams carbohydrate)
Number of subjects: 11
Study 17001146 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training
Number of subjects: 10
Study 17001146 — intervention group
Group type: COMPARATOR
Intervention: Traditional trainer-based training
Number of subjects: 10
Study 15210261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group (12 min preparation with sensory and procedural information)
Number of subjects: 45
Study 15210261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/behavioural group (cognitive preparation plus instruction in deep breathing exercises, tongue depressor task and swallowing technique)
Number of subjects: 45
Study 15210261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 11171290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous combined HRT (Kliogest(R); 2 mg of oestradiol + 1 mg of norethisterone)
Number of subjects: 32
Study 11171290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9632183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterially administered papaverine
Number of subjects: 31
Study 9632183 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone for vasospasm (Control)
Number of subjects: 31
Study 8142195 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg twice daily)
Number of subjects: 196
Study 8142195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 3146197 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase treatment
Number of subjects: 10
Study 1415455 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fibronectin
Number of subjects: 272
Study 1415455 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 272
Study 1415455 — intervention group
Group type: COMPARATOR
Intervention: Commercially available artificial tear
Number of subjects: 272
Study 752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VM‐26 and CCNU at full dose
Number of subjects: 71
Study 752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VM‐26 and CCNU (half dose) with daily intake of procarbazine for 20 days
Number of subjects: 71
Study 752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after three cycles of chemotherapy
Number of subjects: 71
Study 752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 71
Study 752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in the dose of CCNU to 60 mg/m2 per cycle
Number of subjects: 71
Study 31496440 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Aphasia Therapy Plus (CIAT-Plus)
Number of subjects: 216
Study 31496440 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Modal Aphasia Treatment (M-MAT)
Number of subjects: 216
Study 31496440 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 216
Study 31496440 — intervention group
Group type: EXPERIMENTAL
Intervention: CIAT-Plus and M-MAT
Number of subjects: 216
Study 27894852 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed bupivacaine 0.5% (15mL at 37°C)
Number of subjects: 80
Study 27894852 — intervention group
Group type: COMPARATOR
Intervention: Cold bupivacaine 0.5% (15mL at 13-15°C)
Number of subjects: 80
Study 25544718 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralympic-level ID sport footage and information
Number of subjects: 114
Study 25544718 — intervention group
Group type: COMPARATOR
Intervention: Olympic footage and information
Number of subjects: 114
Study 23604333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 52
Study 23604333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22142713 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extension training with pelvic stabilization (STAB; n=15)
Number of subjects: 42
Study 22142713 — intervention group
Group type: COMPARATOR
Intervention: Lumbar extension training without pelvic stabilization (NO-STAB; n=15)
Number of subjects: 42
Study 22142713 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 42
Study 19520162 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched yogurt drink
Number of subjects: 12
Study 19520162 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol consumption (test group)
Number of subjects: 12
Study 19520162 — intervention group
Group type: COMPARATOR
Intervention: No phytosterol consumption (control group)
Number of subjects: 12
Study 19520162 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol consumption
Number of subjects: 12
Study 17305708 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (BR-Tr) with dynamic calf-raise and leg-press exercises
Number of subjects: 12
Study 17305708 — intervention group
Group type: COMPARATOR
Intervention: Control group (BR-Con) with no strength training
Number of subjects: 12
Study 17305708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BR-Con and BR-Tr)
Number of subjects: 12
Study 14668275 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (780 kcal)
Number of subjects: 60
Study 14668275 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber meal (780 kcal)
Number of subjects: 60
Study 14668275 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fiber meal (780 kcal)
Number of subjects: 60
Study 14668275 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic subjects (control group)
Number of subjects: 60
Study 14668275 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 60
Study 10955751 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak expiratory flow monitoring with educational intervention
Number of subjects: 100
Study 10955751 — intervention group
Group type: COMPARATOR
Intervention: Control group with educational intervention and symptom-based self-management
Number of subjects: 100
Study 8843633 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐T and DTP vaccines combined in the same syringe
Number of subjects: 251
Study 8843633 — intervention group
Group type: COMPARATOR
Intervention: PRP‐T and DTP vaccines given separately
Number of subjects: 251
Study 1345953 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/ml rPDGF‐BB
Number of subjects: 20
Study 1345953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6374562 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 0
Study 6374562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Number of subjects: 0
Study 6374562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31456498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (LUM/IVA)
Number of subjects: 21
Study 28637033 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice rinsing (pH 3.8)
Number of subjects: 30
Study 28637033 — intervention group
Group type: COMPARATOR
Intervention: Water rinsing (pH 6.7)
Number of subjects: 30
Study 28637033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rinsing solutions
Number of subjects: 30
Study 25489785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg
Number of subjects: 334
Study 25489785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 15 mg/kg
Number of subjects: 334
Study 25489785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 20 mg/kg
Number of subjects: 334
Study 25489785 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg (Control)
Number of subjects: 334
Study 23850060 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during an insulin tolerance test (ITT)
Number of subjects: 8
Study 21934055 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management plus CBT
Number of subjects: 124
Study 21934055 — intervention group
Group type: COMPARATOR
Intervention: Medication management plus instructions in CBT
Number of subjects: 124
Study 21934055 — intervention group
Group type: COMPARATOR
Intervention: Medication management only
Number of subjects: 124
Study 19207734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diary method
Number of subjects: 12
Study 19207734 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate plate method
Number of subjects: 12
Study 16476920 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg twice daily or once daily (with a 40-mg loading dose)
Number of subjects: 829
Study 16476920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg 4 times daily
Number of subjects: 829
Study 16476920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 16476920 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 829
Study 16476920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 829
Study 15248005 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 60
Study 15248005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11284820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital View laryngoscope
Number of subjects: 100
Study 11284820 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal fibrelight laryngoscope
Number of subjects: 100
Study 11284820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital View laryngoscope with prevention of light emission from the side
Number of subjects: 100
Study 9179510 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day s.l. buprenorphine
Number of subjects: 8
Study 9179510 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (10 mg 70 kg i.m.) during 8 mg buprenorphine maintenance
Number of subjects: 8
Study 9179510 — intervention group
Group type: COMPARATOR
Intervention: Placebo dosing after 8 or 16 mg s.l. buprenorphine
Number of subjects: 8
Study 9179510 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine maintenance (8 mg/day)
Number of subjects: 8
Study 8144233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt chloride (soluble cobalt compound)
Number of subjects: 23
Study 8144233 — intervention group
Group type: COMPARATOR
Intervention: Cobalt oxide (insoluble cobalt compound)
Number of subjects: 23
Study 8144233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt in blood and urine (normal levels)
Number of subjects: 23
Study 3513714 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation by rotahaler
Number of subjects: 15
Study 3513714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilting the head back during inhalation and holding the breath for 10 seconds
Number of subjects: 15
Study 3513714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotahaler treatment
Number of subjects: 15
Study 31269580 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (0.5% racanisodamine eyedrops twice a day during semesters, 1% atropine eyedrops before sleep during vacation)
Number of subjects: 150
Study 31269580 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine group (1% atropine eyedrops before sleep every day)
Number of subjects: 150
Study 31269580 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no medication)
Number of subjects: 150
Study 28490353 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrolling layout of surveys
Number of subjects: 530
Study 28490353 — intervention group
Group type: COMPARATOR
Intervention: Paging layout of surveys
Number of subjects: 530